40 citations
,
April 1999 in “Drugs” Finasteride treats enlarged prostate, improves urinary flow, but may cause sexual side effects.
May 2008 in “10th European Congress of Endocrinology” Flutamide alone is as effective as the combination with finasteride for treating hirsutism.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
September 2010 in “European Urology Supplements” January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
February 2006 in “Inpharma Weekly” January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
402 citations
,
August 2011 in “Cancer research” Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
17 citations
,
December 2015 in “Bioorganic & Medicinal Chemistry” 3-tetrazolo steroidal analogs can strongly inhibit the enzyme linked to hair loss.
July 2026 in “Research Square” Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
1 citations
,
April 2023 in “World Journal of Urology” Finasteride reduces some inflammation in BPH but not all.
3 citations
,
January 2019 in “Therapeutic advances in urology” WS PRO 160 I 120 mg effectively treats urinary symptoms from BPH with good safety and tolerability.
3 citations
,
March 2016 in “Phytotherapy Research” The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
2 citations
,
January 2011 in “Andrologia” Flutamide and a new synthetic steroid affected brain and prostate chemicals and showed potential for treating androgen-related conditions and epilepsy.
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.
September 2023 in “Forum Dermatologicum” Dutasteride injections can help treat hair loss in men and women.
98 citations
,
August 2004 in “BJU international” Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.
11 citations
,
June 2016 in “European Journal of Medicinal Chemistry” Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.
March 2008 in “European Urology Supplements” Finasteride and dutasteride can affect sexual function in BPH patients.
October 2024 in “American Journal of Case Reports” Baricitinib improved hair loss and arthritis in a lupus patient.
2 citations
,
June 2009 in “PubMed” January 2004 in “Actualidad en farmacología y terapéutica” Combining doxazosin and finasteride is more effective for managing benign prostatic hyperplasia than using either drug alone.
May 2024 in “Reactions weekly”